US and China find escape route for biotech industry amid investment curbs

US: The United States government, under President Donald Trump, has proposed draft rules from the Treasury Department to restrict outbound investments in sensitive sectors including biotechnology in countries such as China. The news indicates that US policymakers have incorporated provisions allowing limited engagement in biotech, providing an escape route from stricter national security curbs already applied to semiconductors and AI. This reflects efforts to balance competition with pragmatic cooperation in critical health industries. China: China maintains significant involvement in global pharmaceutical supply chains and biotechnology innovation as part of its strategic industrial plans. The news describes how Beijing has engaged with Washington to secure carve-outs that prevent complete isolation of its biotech sector from US investment. This approach supports ongoing collaboration in medicines amid broader US-China tensions. opinion: Bloomberg Opinion produces analysis and commentary on global business, economics, technology, and geopolitics through its team of columnists. It published the article by Juliana Liu detailing the escape route for Chinese biotech from US investment restrictions. The platform frequently covers US-China relations in strategic sectors like pharmaceuticals. Julian Liu: Juliana Liu serves as a columnist for Bloomberg Opinion's Asia team, focusing on corporate strategy, management, and regional business developments. She authored the opinion piece highlighting the US-China biotech agreement as a timely and constructive outcome. Her prior experience includes roles as senior business editor at CNN Asia and correspondent positions at BBC News and Reuters. Policy: The US Treasury Department recently unveiled draft rules extending national security reviews to Chinese pharmaceutical investments. Cooperation: Washington and Beijing appear to have applied strategic principles to preserve some biotech ties rather than pursuing full decoupling. Industry Impact: Both nations recognize the value of continued collaboration in innovative medicines despite competitive pressures in other tech areas.